Complement system and age-related macular degeneration: drugs and challenges

References

• Miller JW. Age-related macular degeneration revisited–piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2013;155(1):1–35.e13. doi:10.1016/j.ajo.2012.10.01823245386
   PubMed Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e111. doi:10.1016/S2214-109X(13)70145-125104651
   PubMed Web of Science ®Google Scholar
• Song P, Du Y, Chan KY, Theodoratou E, Rudan I. The national and subnational prevalence and burden of age-related macular degeneration in China. J Glob Health. 2017;7(2):020703. doi:10.7189/jogh.07.02070329302323
   PubMed Web of Science ®Google Scholar
• Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379:1728–1738. doi:10.1016/S0140-6736(12)60282-722559899
   PubMed Web of Science ®Google Scholar
• Nebbioso M, Lambiase A, Cerini A, Limoli GP, La Cava M, Greco A. Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules. Int J Mol Sci. 2019;20:7. doi:10.3390/ijms20071693
   Web of Science ®Google Scholar
• Modenese A, Gobba F. Macular degeneration and ocupational risk factors: a systematic review. Int Arch Occup Environ Health. 2019;92(1):1–11. doi:10.1007/s00420-018-1355-y.
   Web of Science ®Google Scholar
• Wong CW, Yanagi Y, Lee W-K, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107–139. doi:10.1016/j.preteyeres.2016.04.00227094371
   PubMed Web of Science ®Google Scholar
• Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol. 2013;13(6):438–451. doi:10.1038/nri345923702979
   PubMed Web of Science ®Google Scholar
• Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14(7):835–846.10783137
   PubMed Web of Science ®Google Scholar
• McHarg S, Clark SJ, Day AJ, Bishop PN. Age-related macular degeneration and the role of the complement system. Mol Immunol. 2015;67:43–50. doi:10.1016/j.molimm.2015.02.03225804937
   PubMed Web of Science ®Google Scholar
• Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887–896. PubMed: 11846519. doi:10.1006/exer.2001.109411846519
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–389. doi:10.1126/science.110955715761122
   PubMed Web of Science ®Google Scholar
• Saksens NTM, Geerlings MJ, Bakker B, et al. Rare genetic variants associated with development of age-related macular degeneration. JAMA Ophthalmol. 2016;134(3):287–293. doi:10.1001/jamaophthalmol.2015.559226767664
   PubMed Web of Science ®Google Scholar
• Geerlings MJ, de Jong EK, Den Hollander AI. The complement system in age-related macular degeneration: a review of rare genetic variants and implications for personalized treatment. Mol Immunol. 2017;84:65–76. doi:10.1016/j.molimm.2016.11.01627939104
   PubMed Web of Science ®Google Scholar
• Khandhadia S, Cipriani V, Yates JRW, Lotery AJ. Age-related macular degeneration and the complement system. Immunobiology. 2012;217(2):127–146. doi:10.1016/j.imbio.2011.07.01921868123
   PubMed Web of Science ®Google Scholar
• Dolgin E. Age-related macular degeneration foils drugmakers. Nat Biotechnol. 2017;35(11):1000–1001. doi:10.1038/nbt1117-100029121027
   PubMed Web of Science ®Google Scholar
• Osthoff M, Dean MM, Baird PN, et al. Association study of mannose-binding lectin levels and genetic variants in lectin pathway proteins with susceptibility to age-related macular degeneration: a case-control study. PLoS One. 2015;10(7):e0134107. doi:10.1371/journal.pone.013410726207622
   PubMed Web of Science ®Google Scholar
• Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology. 2009;215(1):1–11. doi:10.1016/j.imbio.2009.08.00619783065
   PubMed Web of Science ®Google Scholar
• Loyet KM, DeForge LE, Katschke KJ, et al. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(10):6628–6637. doi:10.1167/iovs.12-958722930722
   PubMed Web of Science ®Google Scholar
• Lorthiois E, Anderson K, Vulpetti A, et al. Discovery of highly potent and selective small-molecule reversible factor D inhibitors demonstrating alternative complement pathway inhibition in vivo. J Med Chem. 2017;60(13):5717–5735. doi:10.1021/acs.jmedchem.7b0042528621538
   PubMed Web of Science ®Google Scholar
• Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411–431. PubMed: 12208254. doi:10.1016/S0002-9394(02)01624-012208254
   PubMed Web of Science ®Google Scholar
• Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res. 2004;78:243–256. PubMed: 14729357. doi:10.1016/j.exer.2003.10.01114729357
   PubMed Web of Science ®Google Scholar
• Hageman GS, Mullins RF. Molecular composition of drusen as related to substructural phenotype. Mol Vis. 1999;5:28 PubMed: 10562652.10562652
   PubMed Web of Science ®Google Scholar
• Dobó J, Kocsis A, Gál P. Be on target: strategies of targeting alternative and lectin pathway components in complement-mediated diseases. Front Immunol. 2018;9:1851. doi:10.3389/fimmu.2018.0185130135690
   PubMed Web of Science ®Google Scholar
• Bora PS, Sohn J-H, Cruz JMC, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol. 2005;174(1):491–497. doi:10.4049/jimmunol.174.1.49115611275
   PubMed Web of Science ®Google Scholar
• Zipfel PF. Complement and immune defense: from innate immunity to human diseases. Immunol Lett. 2009;126(1–2):1–7. doi:10.1016/j.imlet.2009.07.00519616581
   PubMed Web of Science ®Google Scholar
• Weber BH, Charbel Issa P, Pauly D, Herrmann P, Grassmann F, Holz FG. The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int. 2014;111:133–138.24622760
   PubMed Web of Science ®Google Scholar
• Gorham RD, Forest DL, Tamamis P, et al. Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures. Exp Eye Res. 2013;116:96–108. doi:10.1016/j.exer.2013.07.02323954241
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45(4):423–440. doi:10.1111/eci.1241925678219
   PubMed Web of Science ®Google Scholar
• Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol. 2013;6(5):565–579. doi:10.1586/17512433.2013.82964523971874
   PubMed Web of Science ®Google Scholar
• Chi Z-L, Yoshida T, Lambris JD, Iwata T. Chapter 9. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol. 2010;703:127–135. doi:10.1007/978-1-4419-5635-4_920711711
   PubMed Web of Science ®Google Scholar
• Collier RJ, Smith S, Hoang H, et al. AL-78898A inhibits complement deposition in a primate light damage model. Invest Ophthalmol Vis Sci. 2012;53(14):5362.22714892
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Alcon research evaluation of AL-78898A in exudative age-related macular degeneration (RACE). 2013 NLM identifier: NCT01157065 Available from: https://clinicaltrials.gov/ct2/show/NCT01157065?term=01157065&rank=1.
   Google Scholar
• ClinicalTrials.gov. Alcon research a multicenter, proof-of-concept study of intravitreal AL-78898A in patients with Geograhic Atrophy (GA) associated with Age-Related Macular Degeneration (AMD). 2013 NLM identifier: NCT01603043 Available from: https://clinicaltrials.gov/ct2/show/NCT01603043?term=01603043&rank=1.
   Google Scholar
• What APL-2 means for geographic atrophy, Michelle Dalton, ELS. 7 22, 2018 Available from: http://www.modernretina.com/asrs/what-apl-2-means-geographic-atrophy. Accessed 74, 2019.
   Google Scholar
• Apellis Pharmaceuticals. Apellis Pharmaceuticals announces that APL-2 met its primary endpoint in a phase 2 study in patients with geographic atrophy, an advanced form of age-related macular degeneration. 8 24, 2017 Available from: http://apellis.com/pdfs/Press%20Release%20FILLY%2012%20Month%20Results%20FINAL%20FINAL%20170823.pdf. Accessed 216, 2018.
   Google Scholar
• Apellis’ geographic atrophy treatment meets phase 2 endpoint. Available from: https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7bb24b7e1c-61fb-4b8b-baaa-13590a87dcec%7d/apellis-geographic-atrophy-treatment-meets-phase-2-endpoint. Accessed 74, 2019.
   Google Scholar
• APL-2 slows growth of GA in phase II safety and efficacy trial by Steve Lenier. 2 26, 2018 Available from: http://www.modernretina.com/amd/apl-2-slows-growth-ga-phase-ii-safety-and-efficacy-trial. Accessed 74, 2019.
   Google Scholar
• ClinicalTrials.gov. Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with Geographic Atrophy (GA) secondary to age-related macular degeneration. 2018 NLM identifier: NCT03525600 Available from: https://clinicaltrials.gov/ct2/show/NCT03525600?term=03525600&rank=1.
   Google Scholar
• Brockmann C, Brockmann T, Dege S, et al. Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2015;253(10):1695–1704. doi:10.1007/s00417-015-3041-z
   PubMed Web of Science ®Google Scholar
• Toomey CB, Landowski M, Klingeborn M, et al. Effect of Anti-C5a therapy in a murine model of early/intermediate dry age-related macular degeneration. Invest Ophthalmol Vis Sci. 2018;59(2):662–673. doi:10.1167/iovs.17-2313429392311
   PubMed Web of Science ®Google Scholar
• Yehoshua Z, Filho CADAG, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121(3):693–701. doi:10.1016/j.ophtha.2013.09.04424289920
   PubMed Web of Science ®Google Scholar
• Mullins RF, Warwick AN, Sohn EH, Lotery AJ. From compliment to insult: genetics of the complement system in physiology and disease in the human retina. Hum Mol Genet. 2017;26(R1):R51–R57. doi:10.1093/hmg/ddx18128482029
   PubMed Web of Science ®Google Scholar
• Loyet KM, Good J, Davancaze T, et al. Complement inhibition in cynomolgus monkeys by anti-factor D antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration. J Pharmacol Exp Ther. 2014;351(3):527–537. In this important preclinical study of the anti-FD antibody lampalizumab, the researchers elucidate important aspects of local and systemic administration of a complement inhibitor considered for AMD treatment. doi:10.1124/jpet.114.21592125232192
   PubMed Web of Science ®Google Scholar
• Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26–47. doi:10.1038/nrneph.2017.15629199277
   PubMed Web of Science ®Google Scholar
• Katschke KJ, Xi H, Cox C, et al. Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy. Sci Rep. 2018;8(1):7348. doi:10.1038/s41598-018-25557-829743491
   PubMed Web of Science ®Google Scholar
• de Jorge EG, Yebenes H, Serna M, Tortajada A, Llorca O, de Córdoba SR. How novel structures inform understanding of complement function. Semin Immunopathol. 2018;40(1):3–14. doi:10.1007/s00281-017-0643-z28808775
   PubMed Web of Science ®Google Scholar
• Chirco KR, Tucker BA, Stone EM, Mullins RF. Selective accumulation of the complement membrane attack complex in aging choriocapillaris. Exp Eye Res. 2015;146:393–397. doi:10.1016/j.exer.2015.09.00326368849
   PubMed Web of Science ®Google Scholar
• Cashman SM, Ramo K, Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One. 2011;6(4):e19078. doi:10.1371/journal.pone.001907821552568
   PubMed Web of Science ®Google Scholar
• Roguska M, Splawski I, Diefenbach-Streiber B, et al. Generation and characterization of LFG316, a fully-human anti-C5 antibody for the treatment of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2014;55(13):3433.
   Web of Science ®Google Scholar
• LFG316 Found Ineffective. Available from: https://www.mdfoundation.com.au/content/lfg316-ineffective-dry-age-related-macular-degeneration. Accessed 74, 2019.
   Google Scholar
• Anti-complement C5 monotherapy ineffective in reducing geographic atrophy lesion size. 2016 Available from: https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Bb24258c2-0a16-425c-9476-a591485d3cf6%7D/anti-complement-c5-monotherapy-ineffective-in-reducing-geographic-atrophy-lesion-size. Accessed 74, 2019.
   Google Scholar
• Ophthotech. Ophthotech provides update on Zimura complement programs for treatment of eye diseases. 9 19, 2017 Available from: https://www.streetinsider.com/FDA/Ophthotech+Corp.+(OPHT)+Reports+Completion+of+Patient+Recruitment+in+the+Phase+2a+Clinical+Trial+of+Zimura+in+Combination+with+Anti-VEGF+Therapy/14123271.html.
   Google Scholar
• ClinicalTrials.gov. ZIMURA in combination with LUCENTIS in patients with Neovascular Age Related Macular Degeneration (NVAMD). 2017. NLM identifier: NCT03362190.
   Google Scholar
• ClinicalTrials.gov. Zimura in subjects with geographic atrophy secondary to dry age-related macular degeneration. 2016. NLM identifier: NCT02686658.
   Google Scholar
• Katschke KJ, Wu P, Ganesan R, et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J Biol Chem. 2012;287(16):12886–12892. doi:10.1074/jbc.M112.34508222362762
   PubMed Web of Science ®Google Scholar
• Volanakis JE, Barnum SR, Giddens M, et al. Renal filtration and catabolism of complement protein D. N Engl J Med. 1985;312:395–399. doi:10.1056/NEJM1985021431207023844050
   PubMed Web of Science ®Google Scholar
• Jack LS, Sadiq MA, Do DV, Nguyen QD. Emixustat and lampalizumab: potential therapeutic options for geographic atrophy. Retinal Pharmacotherapeutics. n.d.;302–309. doi:10.1159/000438954
   Google Scholar
• Crowley MA, Delgado O, Adrian Will-Orrego NM, et al. Induction of ocular complement activation by inflammatory stimuli and intraocular inhibition of complement factor D in animal models. Invest Ophthalmol Vis Sci. 2018;59(2):940–951. doi:10.1167/iovs.17-2260529450541
   PubMed Web of Science ®Google Scholar
• van Lookeren Campagne M, Katschke KJ Jr, Wu P, et al. Targeting the alternative pathway of complement in AMD with a factor D selective antibody. Invest Ophthalmol Vis Sci. 2010;51(13):4511.
   Web of Science ®Google Scholar
• Do DV, Pieramici DJ, van Lookeren Campagne M, et al. A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina. 2014;34:313–320. doi:10.1097/IAE.0b013e3182979ddd23842100
   PubMed Web of Science ®Google Scholar
• Holz, F. G. The MAHALO Phase 2 Study: Safety, Tolerability and Evidence of Activity of Lampalizumab (Anti-factor D) in Patients with Geographic Atrophy(GA) Secondary to Age-Related Macular Degeneration(AMD). in Euretina Meeting  28. Sept, 2013.
   Google Scholar
• Roche. Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration. 2017 Available from: https://www.roche.com/media/store/releases/med-cor-2017-09-08b.htm. Accessed 74, 2019.
   Google Scholar
• Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136(6):666–677. doi:10.1001/jamaophthalmol.2018.154429801123
   PubMed Web of Science ®Google Scholar
• Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med. 2017;9(395):eaaf1443. doi:10.1126/scitranslmed.aaf144328637922
   PubMed Web of Science ®Google Scholar
• Dobó J, Pál G, Cervenak L, Gál P. The emerging roles of mannose-binding lectin-associated serine proteases (MASPs) in the lectin pathway of complement and beyond. Immunol Rev. 2016;274(1):98–111. doi:10.1111/imr.1246027782318
   PubMed Web of Science ®Google Scholar
• Volz C, Pauly D. Antibody therapies and their challenges in the treatment of age-related macular degeneration. Eur J Pharm Biopharm. 2015;95:158–172. doi:10.1016/j.ejpb.2015.02.02025725263
   PubMed Web of Science ®Google Scholar
• Wolf-Schnurrbusch UE, Stuck AK, Hess R, Wolf S, Enzmann V. Complement Factor P in choroidal neovascular membranes of patients with age-related macular degeneration. Retina. 2009;29(7):966–973. doi:10.1097/IAE.0b013e3181a2f40f19584655
   PubMed Web of Science ®Google Scholar
• Chen JY, Cortes C, Ferreira VP. Properdin: A multifaceted molecule involved in inflammation and diseases. Mol Immunol. 2018;102:58–72. doi:10.1016/j.molimm.2018.05.01829954621
   PubMed Web of Science ®Google Scholar
• Gupta-Bansal R, Parent JB, Brunden KR. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol. 2000;37:191–201.10930626
   PubMed Web of Science ®Google Scholar
• Pauly D, Nagel BM, Reinders J, et al. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One. 2014;9:e96371. doi:10.1371/journal.pone.009637124797388
   PubMed Web of Science ®Google Scholar
• Lesher A, Nilsson B, Song W-C. Properdin in complement activation and tissue injury. Mol Immunol. 2013;56(3):191–198. doi:10.1016/j.molimm.2013.06.00223816404
   PubMed Web of Science ®Google Scholar
• Pipeline for dry AMD features diverse compounds. Modern medicine feature articles, modern medicine feature articles, ophthalmology. 4 15, 2016 Available from: http://www.ophthalmologytimes.com/modern-medicine-feature-articles/pipeline-dry-amd-features-diverse-compounds. Accessed 74, 2019.
   Google Scholar
• ClinicalTrials.gov. Pharmacokinetics of CLG561 in patients with advanced age-related macular degeneration. 2013. NLM identifier: NCT01835015.
   Google Scholar
• ClinicalTrials.gov. CLG561 proof-of-concept study as a monotherapy and in combination with LFG316 in subjects with Geographic Atrophy (GA). 2015. NLM identifier: NCT02515942.
   Google Scholar
• Bansal R. Method of inhibiting complement activation with factor Bb specific antibodies WO2009/029669A1. 2009.
   Google Scholar
• Fernandez-Godino R, Pierce EA. C3a triggers formation of sub-retinal pigment epithelium deposits via the ubiquitin proteasome pathway. Sci Rep. 2018;8:9679. doi:10.1038/s41598-018-28143-029946065
   PubMed Web of Science ®Google Scholar
• Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38(4):458–462. doi:10.1038/ng175016518403
   PubMed Web of Science ®Google Scholar
• Grossman TR, Carrer M, Shen L, et al. Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide. Mol Vis. 2017;23:561–571.28855795
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety and efficacy of IONIS-FB-Lrx in up to 120 patients 55 and older with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). NLM identifier: NCT03446144 Available from: https://clinicaltrials.gov/ct2/show/NCT03446144?term=IONIS-FB-Lrx&rank=2.
   Google Scholar
• Thurman JM, Kraus DM, Girardi G, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005;42(1):87–97. doi:10.1016/j.molimm.2004.07.04315488947
   PubMed Web of Science ®Google Scholar
• Ren X, Li J, Xu X, Wang C, Cheng Y. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys. Exp Eye Res. 2016;145:352–358. doi:10.1016/j.exer.2016.02.00426919788
   PubMed Web of Science ®Google Scholar
• Sayegh RG, Sacu S, Dunavölgyi R, et al. Geographic atrophy and foveaal-sparing changes related to visual acuity in patients with dry age-related macular degeneration over time. Am J Ophthalmol. 2017;179:118–28.una. doi:10.1016/j.ajo.2017.03.03128385474
   PubMed Web of Science ®Google Scholar
• Garrity ST, Sarraf D, Freund KB, Sadda SR. Multimodal imaging of nonneovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2018;59(4):AMD48–AMD64. doi:10.1167/iovs.18-2415830025107
   PubMed Web of Science ®Google Scholar
• de Amorim Garcia Filho C, Yehoshua Z, Gregori G, et al. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2014;45:18–31. doi:10.3928/23258160-20131217-0124354307
   PubMed Web of Science ®Google Scholar
• Simader C, Sayegh RG, Montuoro A, et al. A longitudinal comparison of spectral-domain optical coherence tomography and fundus autofluorescence in geographic atrophy. Am J Ophthalmol. 2014;158:557–566.e1. doi:10.1016/j.ajo.2014.05.02624879944
   PubMed Web of Science ®Google Scholar
• Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125(3):369–390. doi:10.1016/j.ophtha.2017.08.03829110945
   PubMed Web of Science ®Google Scholar
• Lindner M, Nadal J, Mauschitz MM, et al. Combined fundus autofluorescence and near infrared reflectance as prognostic biomarkers for visual acuity in foveal-sparing geographic atrophy. Invest Ophthalmol Vis Sci. 2017;58(6):BIO61. doi:10.1167/iovs.16-2121028475704
   PubMed Web of Science ®Google Scholar
• Liu MM, Chan CC, Tuo J. Genetic mechanisms and age-related macular degeneration: common variants, rare variants, copy number variations, epigenetics, and mitochondrial genetics. Hum Genomics. 2012;6(1):13. doi:10.1186/1479-7364-6-1323244519
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Iartchouk O, Chin K, et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet. 2011;43:1232–1236. doi:10.1038/ng.97622019782
   PubMed Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131–1135. doi:10.1016/j.addr.2006.07.02717097758
   PubMed Web of Science ®Google Scholar
• Moisseiev E, Loewenstein A. Drug delivery to the posterior segment of the eye. Dev Ophthalmol. 2017;87–101. doi:10.1159/00045527628351054
   PubMedGoogle Scholar
• Joseph RR, Tan DWN, Ramon MRM, et al. Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab. Sci Rep. 2017;7:16803. doi:10.1038/s41598-017-16791-729196745
   PubMed Web of Science ®Google Scholar
• Pennesi ME, Neuringer M, Courtney RJ. Animal models of age related macular degeneration. Mol Aspects Med. 2012;33(4):487–509. doi:10.1016/j.mam.2012.06.00322705444
   PubMed Web of Science ®Google Scholar